ESMO 2023 | Impact of a minimal versus CT-scan-based follow-up on PROs for resected NSCLC in IFCT-0302

Guillaume Eberst, MD, University Hospital of Besancon, Besancon, France, discusses results from the IFCT-0302 trial (NCT00198341), a randomized multicenter study, investigated the impact of adding chest CT-scan and fiberoptic bronchoscopy to the follow-up after resection of non-small cell lung cancer (NSCLC). Patient-reported outcomes (PROs) were assessed as a secondary endpoint, including Health-Related Quality of Life (HRQoL). Among 1775 patients, no significant difference in time to deterioration was found in HRQoL between the minimal follow-up and CT-based follow-up groups. However, penibility was higher in the CT-based follow-up group, attributed to fiberoptic bronchoscopy. These findings suggest that the additional thoracic CT-scan did not affect HRQoL but increased patient discomfort.This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.